[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351705-105":59,"doc-detail-351705-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","kras-and-myc-synergistic-inhibition-a-powerful-strategy-targeting-kras-mutant-cancers","KRAS and MYC synergistic inhibition - a powerful strategy targeting KRAS-mutant cancers","","KRAS is a critical proto-oncogene whose signaling activity is driven by oncogenic mutations, while MYC dysregulation promotes tumor progression and has long been viewed as difficult to drug. Coordinated KRAS activation and MYC upregulation cooperate in tumorigenesis, motivating dual oncogene inhibition as a synergistic therapeutic approach for KRAS-mutant cancers. The mechanistic basis remains unclear due to complex functional crosstalk. This review analyzes their roles in metabolic reprogramming, epigenetic remodeling, and immune-suppressive tumor microenvironments, surveys anti-KRAS strategies, and discusses therapy resistance linked to MYC dysregulation, emphasizing concurrent pathway targeting to overcome KRAS-driven malignancies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kras-and-myc-synergistic-inhibition-a-powerful-strategy-targeting-kras-mutant-cancers/351705/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kras-and-myc-synergistic-inhibition-a-powerful-strategy-targeting-kras-mutant-cancers/351705.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KRAS considered difficult to target therapeutically?","Question",{"text":112,"@type":113},"KRAS lacks distinct high-affinity small-molecule binding pockets and has exceptionally strong intracellular GTP affinity, which creates a major competitive barrier for inhibitor design.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does synergistic inhibition of KRAS and MYC aim to achieve?",{"text":117,"@type":113},"The approach targets coordinated KRAS-driven signaling and MYC dysregulation that together fuel tumorigenesis, aiming to improve therapeutic effectiveness in KRAS-mutant cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How can resistance to KRAS-targeted therapies arise in the context of MYC dysregulation?",{"text":121,"@type":113},"Resistant tumors can bypass KRAS inhibition by reactivating MYC to maintain proliferation and survival, suggesting combined interventions targeting these adaptive pathways may help overcome resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351705,1790268974,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Yan et al. Molecular Cancer (2026) 25:139 [https://doi.org/10.1186/s12943-026-02659-w](https://doi.org/10.1186/s12943-026-02659-w)  \nMolecular Cancer  \nREVIEW Open Access  \nKRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers  \nMan Yan1†, Kai Liu2†, Jing Xu3, Yandi Liu4, Liechen Ji5 and Shiwu Zhang6*  \nAbstract  \nKRAS is a critical proto-oncogene that encodes a protein functioning as a pivotal molecular switch in intracellular signaling. Both KRAS mutations and MYC dysregulation are key drivers of tumor progression and have historically been regarded as “undruggable” targets. Emerging evidence underscores that the coordinated activation of KRASand MYC cooperatively fuels tumorigenesis, suggesting that dual inhibition of these oncogenes may constitute a synergistic therapeutic approach for KRAS-mutant cancers. However, the mechanistic basis underlying the effective combined targeting of KRAS and MYC remains poorly defined, largely due to the complexity of their functional interplay. This review examines their collaborative roles in metabolic reprogramming, epigenetic remodeling, and shaping an immunosuppressive tumor microenvironment through crosstalk with immune cells. It also surveys current and emerging anti-KRAS strategies and discusses the challenge of therapy resistance, particularly in the setting of MYC dysregulation. Since resistant tumors often circumvent KRAS inhibition by reactivating MYC to sustain proliferation and survival, interventions that concurrently target these adaptive pathways may hold promise for overcoming resistance in KRAS-driven malignancies.  \nKeywords KRAS-mutant, Cancer, MYC, Tumor immune microenvironment, Epigenetic modification, Transcriptome, Metabolic reprogramming  \n†Man Yan and Kai Liu contributed equally to this work.  \n*Correspondence:  \nShiwu Zhang  \n[zhangshiwu666@aliyun.com](zhangshiwu666@aliyun.com)  \n1Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China  \n2Department of Research and Education, Tianjin Beichen Hospital, Tianjin, China  \n3Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, P. R. China 4Department of Gastroenterology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China 5Department of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, P. R. China 6Department of Pathology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, P. R. China  \nIntroduction  \nKirsten rat sarcoma viral (KRAS) is a highly prevalent oncogene with the highest mutation frequency in various cancer types, such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC) [1]. For over three decades, KRAS has been a well-validated therapeutic target, yet its unique structural features have rendered it largely “undruggable”. The primary challenges are the absence of distinct, high-affinity small-molecule binding pockets and the protein’s exceptionally strong affinity for intracellular guanosine triphosphate (GTP), posing a substantial competitive challenge for inhibitor design. Consequently, the development of specific inhibitors to block KRAS-driven oncogenesis remains a formidable hurdle [2]. However,  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. Th","cbCaicTOzEaUiLBI","https://ap.wps.com/l/cbCaicTOzEaUiLBI","pdf",4188621,24,"English","# Abstract\n# Introduction\n## KRAS as an undruggable target\n## Advances in KRAS-targeted therapy\n## Direct KRAS[G12C] inhibition and resistance","[{\"question\":\"Why is KRAS considered difficult to target therapeutically?\",\"answer\":\"KRAS lacks distinct high-affinity small-molecule binding pockets and has exceptionally strong intracellular GTP affinity, which creates a major competitive barrier for inhibitor design.\"},{\"question\":\"What does synergistic inhibition of KRAS and MYC aim to achieve?\",\"answer\":\"The approach targets coordinated KRAS-driven signaling and MYC dysregulation that together fuel tumorigenesis, aiming to improve therapeutic effectiveness in KRAS-mutant cancers.\"},{\"question\":\"How can resistance to KRAS-targeted therapies arise in the context of MYC dysregulation?\",\"answer\":\"Resistant tumors can bypass KRAS inhibition by reactivating MYC to maintain proliferation and survival, suggesting combined interventions targeting these adaptive pathways may help overcome resistance.\"}]","KRAS and MYC synergistic inhibition - a powerful strategy targeting KRAS-mutant cancers | PDF",1790095433,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fba908487f1d2d1bd90c5b7557b78b20.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b8a268e551d558709593a51fa0d4146.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba305614711cae6159a0530ee41af171.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5223de53756c8647418ea1ccf18d38a.webp",980,1306]